Sahajanand Medical Technologies IPOUPCOMING

Sahajanand Medical Technologies Limited (SMT) is a medical device company engaged in the research, development, manufacturing and distribution of advanced cardiovascular devices, primarily focusing on vascular intervention and structural heart procedures. Founded in 2001, the company specialises in Class III and Class C/D medical devices. According to the Frost & Sullivan Report, SMT was the first company globally to receive CE certification for a biodegradable polymer-based paclitaxel-eluting stent, Infinnium.

The company's product portfolio is divided into three major categories:

• Vascular Intervention (VI): Coronary stents, drug-eluting stents and coronary balloons, including its flagship product Supraflex Cruz.
• Structural Heart (SH): Transcatheter Aortic Valve Implantation (TAVI) systems and occluders, including Hydra and Cocoon.
• Other Products: Renal stents, peripheral drug-coated balloons and traded medical devices.

SMT operates three manufacturing facilities across India and Thailand, along with two R&D centres supported by 156 professionals (including four consultants) as of June 30, 2026. The company holds 119 granted patents globally, 78 pending patent applications and five design registrations in India, with its key products supported by 75 clinical studies.

The company marketed its products across 77 countries during FY2026, through direct operations, hybrid distribution and distributor-led models. According to Frost & Sullivan, SMT held approximately 25% market share in India's drug-eluting stent market by sales volume in FY2026.

In FY2026, Vascular Intervention contributed 61.14% of revenue from operations, followed by Structural Heart at 16.77% and Other Products at 22.09%. Approximately 73.87% of revenue came from international markets, reflecting the company's significant global presence.

As of June 30, 2026, Sahajanand Medical Technologies had 1,605 full-time employees, 31 consultants and 707 contract workers, totalling 2,343 personnel.